Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and …

Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …

The role of natural killer (NK) cells in multiple myeloma is not fully understood. Here, NK
susceptibility of myeloma cells derived from distinct disease stages was evaluated in relation to …

Decreased activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma
(MM). The production of the soluble Wnt inhibitor Dickkopf-1 (DKK1) by MM cells inhibits OB …

Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic
endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein …

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable
responses in multiple myeloma. However, relapse following therapy is frequently observed…

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of …

Elevated cytokines in bone marrow (BM) micro-environment (interleukin-6 [IL-6], transforming
growth factor-beta [TGF-β], and IL-1β) may play an important role in observed immune …

Understanding the pathogenesis of cancer-related bone disease is crucial to the discovery
of new therapies. Here we identify activin A, a TGF-β family member, as a therapeutically …